

CELGENE CORP /DE/
Form 8-K
March 29, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 29, 2019

CELGENE CORPORATION

(Exact name of registrant as specified in its charter)

Exchange Act. "

ITEM 8.01 OTHER EVENTS.

On March 29, 2019, Celgene Corporation (“*Celgene*”) announced the settlement of litigation with Lotus Pharmaceutical Co., Ltd. and Alvogen Pine Brook, LLC relating to patents for REVLIMID® (lenalidomide).

Attached hereto and incorporated herein by reference as Exhibit 99.1 is the press release.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

d) Exhibits

99.1 Press Release dated March 29, 2019

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CELGENE CORPORATION

Date: March 29, 2019 By: /s/ David V. Elkins
David V. Elkins
Executive Vice President
Chief Financial Officer
(principal financial and accounting officer)